Recent Articles
NeuExcell Therapeutics and Spark Therapeutics Collaboration
- September 9, 2021
Theobald Associates is pleased to announce the successful completion of a research collaboration agreement between its client NeuExcell Therapeutics and Spark Therapeutics. The research collaboration is in the gene therapy field aimed at developing a safe and effective treatment…
Series A Funding for Theolytics
- July 1, 2021
Theobald Associates is pleased to announce the successful closing of a Series A Fundraising Extension for its client, Theolytics Limited. The transaction funds will be used for the advancement of its viral cancer therapies. Further details can be found…
Successful Closing of a Seed Financing
- July 1, 2021
Theobald Associates is pleased to announce the successful closing of a Seed Financing for its client, QV Bioelectronics Ltd. The transaction funds will be used to advance the development of the GRACE implant, to treat brain tumour patients with…
Exclusive Collaboration and License Agreement
- March 2, 2021
Theobald Associates is pleased to announce the successful completion of an exclusive collaboration and license agreement between its client Reviral Limited and LianBio. The terms of the collaboration, ReViral will receive an upfront cash payment of $14 million and…
Successful Closing of a Series A Fundraising
- December 18, 2020
Theobald Associates is pleased to announce the successful closing of a Series A Fundraising for its client, Theolytics Limited. The transaction raised approximately US $6,800,000 for advance its viral cancer therapies. Further details can be found at: https://www.theolytics.com/post/theolytics-raises-6-8-million-series-a-round-co-led-by-epidarex-capital-and-taiho-ventures
Successful Closing of a Series C Fundraising
- August 18, 2020
Theobald Associates is pleased to announce the successful closing of a Series C Fundraising for its client, Reviral Limited. The transaction raised approximately US $44,000,000 for clinical development. Further details can be found at: https://reviral.co.uk/reviral-raises-44-million-in-series-c-financing
Pro Bono Publico – Incorporation and Initial Funding of 3C
- May 18, 2020
Theobald Associates is pleased to announce that as part of its pro bono publico program it has assisted with the incorporation and initial funding of Collaborative Community Against Coronavirus Community Interest Company. The Company has been formed by a…
Successful Closing of a Seed Funding
- January 31, 2020
Theobald Associates is pleased to announce the successful closing of a seed funding for its client, Ikarovec Limited. The transaction raised approximately £2,500,000 from leading start up investors UKI2S, Lifearc and Parkwalk. The Company intends to use the funds…
Successful Closing of a Capital Raise
- December 18, 2019
Theobald Associates is pleased to announce the successful closing of a capital raise for its client, Genesis Global Technology Limited. The transaction raised approximately US $1,800,000 for the innovative technology firm. Further details can be found at: https://genesis.global/genesis-raises-1-8m-to-fuel-growth-from-illuminate-financial/
Restructuring of Visible Youth
- June 19, 2019
Theobald Associates is pleased to announce the successful completion of the share restructuring of Visible Youth Limited, a UK based skin care company, as part of a Plan of Reorganisation, Liquidation and Dissolution of its former parent Company Enhance…
Successful Investment Round
- April 17, 2019
Theobald Associates is pleased to announce the successful closing of an investment round for its client, Over Under Coffee Limited. The transaction raised approximately £150,000 for the fast-growing London-based Coffee shop chain. Further details can be found HERE.
Series A Fundraising
- April 10, 2019
Theobald Associates is pleased to announce the successful closing of a Series A Fundraising for its long-term client, Visusnano Limited. The transaction raised approximately £400,000 for the Cambridge-based biotechnology company from a syndicate of individual and EIS-based institutional investors….
Successful Series B Funding Round
- March 23, 2019
Theobald Associates is pleased to announce the successful closing of a Series B Fundraising for its long-term Client, Huq Industries Limited. The transaction raised approximately £1.4 for the leading geo-behavioural consumer research platform with the funding round including both…
Series A Fundraising for Genesis Global Technology
- September 10, 2018
Theobald Associates is pleased to announce the successful closing of a Series A Fundraising for its London-based capital markets software client Genesis Global Technology Limited. The transaction raised approximately $3 million for the innovative FinTech with the funding being…
Pro Bono Publico – Period Power
- August 17, 2018
Theobald Associates is pleased to announce that as part of its pro bono publico program it has assisted with the formation and registration of the charity Period Power. The Charity has been formed to supply free sanitary products to…
Sale of Quethera
- August 10, 2018
Theobald Associates is pleased to announce the successful sale of its client Quethera Limited, the Cambridge-based Bio-technology Company, to Astellas Pharma Inc, the Tokyo-based multinational pharmaceutical Company. Under the terms of the Share Purchase Agreement, Astellas may pay up…
Successful closing of B series funding
- July 17, 2018
Theobald Associates is pleased to announce the successful closing of a Series B Fundraising for its client, the UK-based antiviral drug discovery Company Reviral Limited. The transaction raised USD$55 million for the BioTech and will enable it to progress…
Crawford Healthcare Ltd – Successful Sale
- June 8, 2018
Theobald Associates is pleased to announce the successful sale of its UK-based client Crawford Healthcare Limited to the US-based Acelity L.P. Inc., with the transaction creating the World’s most expansive wound care portfolio. Theobald Associates played a supporting role…
Successful Series A
- March 27, 2018
Theobald Associates is pleased to announce the successful closing of a Series A Fundraising for its client, Lal Kila Companies Limited (trading as Hope and Glory). The transaction raised approximately £200,000 for expanding hot beverage supplier. Further details can…
Dalston Cola – Successful Series A
- November 15, 2017
Theobald Associates is pleased to announce the successful closing of a Series A Fundraising for its client the London based organic drinks producer Dalston Cola Company Limited. The transaction raised approximately £600,000 for the growing beverage maker. Further details…
Funding Round Success
- October 26, 2017
Theobald Associates is pleased to announce the successful closing of a successful funding round for its client, the London-based fintech OTCX Ltd. The transaction raised approximately £1 million for the innovative over-the-counter derivatives platform with the funding being supported…
Successful Seed Funding
- October 18, 2017
Theobald Associates is pleased to announce the successful closing of a Seed Funding round for its client, Lal Kila Companies Limited (trading as Hope and Glory). The transaction raised approximately £150,000 for the premium tea supplier. Further details can…
Financing Round
- May 12, 2016
Theobald Associates is pleased to announce the completion of a seed financing round of the expanding organic soft drinks Company Dalston Cola Company Limited. The transaction raised approximately £250,000 for the Soda producer. Further details can be found HERE.
Even Pharma IPO success
- October 20, 2015
Theobald Associates is pleased to announce the successful IPO of its client, the Liverpool-based pharmaceutical, Evgen Pharma. In the AIM stock market float the Company raised £7 million via an oversubscribed share placing. The cash raised by the transaction…
Reviral Limited – Successful Series A
- September 3, 2015
Theobald Associates is pleased to announce the successful closing of a Series A Fundraising for its client, the UK-based antiviral drug discovery Company Reviral Limited. The transaction raised USD$21 million in a funding round lead by a group of…
Canbex Therapeutics Limited – Share Option Agreement by Admin in Uncategorised
- February 24, 2015
Theobald Associates is pleased to announce the successful completion of a share option agreement between its London-based client Canbex Therapeutics Limited and Ipsen, a global speciality-driven Biopharmaceutical. The transaction involved Ipsen paying Euro €6 million up front for the…
Successful Sale of Q Chip Limited
- December 8, 2014
Theobald Associates is pleased to announce the successful sale of its UK-based client Q Chip Limited and its subsidiaries to Midatech Pharma plc. The acquisition was made immediately prior to Midatech’s admission to trading on the AIM Market of…
IPO of Abzena plc
- July 10, 2014
Theobald Associates is pleased to announce the successful sale of its UK-based client Q Chip Limited and its subsidiaries to Midatech Pharma plc. The acquisition was made immediately prior to Midatech’s admission to trading on the AIM Market of…
Antitope – Acquisition
- July 26, 2013
Theobald Associates is pleased to announce the successful acquisition of the Cambridge-based Antitope Limited by its long-term client Polytherics Limited. As part of this transaction Theobald Associates worked in partnership with a team from Fieldfisher. The complex transaction comprised…